相关实验视频

Updated: Jun 14, 2025

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach
10:13

Assessment of Age-related Changes in Cognitive Functions Using EmoCogMeter, a Novel Tablet-computer Based Approach

Published on: February 14, 2014

13.7K

基于智能手机和平板电脑的工具来评估临床前阿尔茨海默病和轻度认知障碍患者的认知能力:范围审查

Rosanne L van den Berg1,2,3, Sophie M van der Landen1,2, Matthijs J Keijzer1,2,4

  • 1Alzheimer Center Amsterdam, Neurology, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Journal of medical Internet research
|May 27, 2025
PubMed
概括

早期阿尔茨海默病 (AD) 检测的数字工具显示出希望,但对其心理特性的严格验证往往缺乏. 需要进一步的研究来确保这些认知评估技术在临床上对广泛实施有用.

关键词:
认知 认知 认知数字生物标志物数字生物标志物数字健康数字健康轻度的认知障碍 轻度的认知障碍临床前阿尔茨海默病阿尔茨海默病心理测量是指心理测量.范围审查 范围审查审查基于智能手机的评估基于平板电脑的评估.

更多相关视频

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment12:18

A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment

Published on: January 11, 2020

7.5K
Transcranial Pulse Stimulation for Alzheimer's Patients06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

478

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
454
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
110
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
107
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
72
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170